Medtronic Partners with Precision Neuroscience to Bring Advanced Brain Mapping to Operating Rooms
New York, Monday, 12 January 2026.
Integrating Precision’s high-resolution interface with Medtronic’s surgical platform, this partnership targets a surging neurotechnology sector projected to reach $16.56 billion by 2033.
Strategic Integration of Neural Technologies
In a move that signals a significant shift in the neurosurgical landscape, Precision Neuroscience Corporation and Medtronic (MDT) officially announced a strategic partnership on January 12, 2026 [1]. The collaboration focuses on co-developing an integrated solution that combines Precision’s Layer 7™ Cortical Interface—a high-resolution, minimally invasive brain-computer interface (BCI)—with Medtronic’s widely utilized StealthStation™ surgical navigation system [1]. The primary objective is to create an end-to-end system capable of delivering real-time functional and structural insights directly within the operating room, a development that Precision CEO Michael Mager describes as a “step change” in bringing advanced brain mapping capabilities into everyday clinical practice [1].
Market Dynamics and Financial Growth
This partnership emerges against the backdrop of a rapidly expanding market for neurostimulation and neurotechnology. As of 2025, the neurostimulation devices market was valued at $6.95 billion, with projections estimating a surge to $16.56 billion by 2033 [3]. This growth trajectory represents a Compound Annual Growth Rate (CAGR) of 11.50% from 2026 to 2033 [3]. Within this sector, Deep Brain Stimulators (DBS) are identified as the fastest-growing segment, expanding at a CAGR of 15.8% [3]. The commercial appetite for such medical technology is further evidenced by a dramatic increase in capital availability; total reported capital raised in med-tech financing reached $39.55 billion in 2025, an increase of 56.016% from the $25.35 billion raised in 2024 [2].
Navigating Regulatory and Clinical Pathways
The alliance leverages Medtronic’s established footprint to mitigate common barriers in the neurotechnology sector. While 84% of U.S. healthcare providers have integrated neurostimulation devices into standard care pathways, regulatory hurdles remain a significant challenge for new entrants [3]. Approximately 75% of neurostimulation device manufacturers have experienced market entry delays of 18 to 24 months due to stringent regulatory requirements [3]. By integrating Precision’s high-volume data processing capabilities with Medtronic’s trusted cranial and spinal platforms, the partnership aims to accelerate the global adoption of adaptive, intelligent therapies and streamline the path to clinical utility [1].